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ABSTRACT
Introduction. One of the most important achievements of contemporary oncology is the discovery of new 
therapeutic possibilities: targeted therapy and immunotherapy associated with checkpoint inhibitors. It has not 
been unequivocally determined so far which therapy should be used as first-line treatment in patients with ad-
vanced/metastatic melanoma with the BRAF mutation.
Material and methods. 137 patients with advanced/metastatic melanoma with the BRAF mutation were analyzed. 
They received anti-PD1-1 therapy (IT) or molecularly targeted therapy iBRAF ± iMEK (TT) as first-line treatment in 
the scope of the national drug program. IT and TT therapies used as first-line treatment were compared.
Results. Median OS and PFS in the group were 14.0 and 7.3 months. Unfavorable prognostic factors for OS and 
PFS were metastases to the central nervous system, increased LDH levels and performance status > 1. Meta-
static sites in > 2 locations were only unfavorable prognostic factors for OS. A statistically significant difference 
was found between TT and IT for OS (p = 0.0011; median for TT was 12.6 months and was not reached for 
IT). It should be noted that the group treated with TT was characterized by a worse prognostic factors. 
No differences in PFS were observed (p = 0.292, medians 7.2 and 9.0 months, respectively). 
Conclusion. In patients with advanced/metastatic melanoma with a BRAF mutation without rapid progression, 
IT should be considered as first-line therapy.
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Introduction
In recent years treatment of patients with a melano-
ma diagnosis has changed greatly. The presence of spe-
cific mutations in melanoma cells, including the BRAF 
[1] mutation, was discovered. The BRAF V600 mutation 
is present in approximately 50% of patients with meta-
static melanoma and is a predictive factor for response 
to targeted therapies [2]. The use of targeted therapies 
with inhibitors of BRAF ± MEK (iBRAF ± iMEK) 
has contributed to a considerable improvement of the 
treatment results in respect to overall survival (OS) 
and progression-free survival (PFS) which has been 
confirmed in randomized trials [3–8]. Moreover, the de-
velopment of immunotherapy associated with immune 
checkpoint inhibitors (ICIs) has improved the results 
of treatment of melanoma patients [9–18]. ICI action 
is independent of the presence of the BRAF mutation 
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[16–19]. Administration of ICIs may lead to long-term 
remission [8–16]. The dominant problem, however, is 
the low percentage of responses to immune checkpoint 
inhibitors as well as the length of time from the moment 
of initiating the therapy to the response to treatment 
[9–16]. The response to targeted therapies is different, 
as the percentage of responses to treatment is high and 
the time to response is very short [3–8].
Systemic treatment of patients with the BRAF mutation 
poses a significant therapeutic challenge. So far the therapy 
which should be applied as first-line treatment has not been 
determined unequivocally in patients with advanced/meta-
static melanoma. There is little data on this subject and the 
results of randomized trials, which would directly compare 
the effectiveness of anti-PD-1 immunotherapy (IT) and tar-
geted therapy iBRAF ± iMEK (TT) as first-line treatment 
in this group of patients are missing [20–26]. Currently, two 
clinical studies are ongoing DREMseg (NCT02224781) 
and SECOMBIT (NCT02631447) and EORTC EBIN 
which should answer to this question but the results are 
still awaited [27].
Therefore we decided to undertake a retrospective 
analysis comparing first-line TT or IT treatment in pa-
tients with advanced/metastatic melanoma with a BRAF 
mutation. The paper presents the analysis of 137 patients 
with advanced/metastatic melanoma with a BRAF muta-
tion who received immunotherapy or targeted therapy 
as first-line treatment.
Material and methods 
All patients with advanced/metastatic melanoma 
treated in the frame of national drug programs from Janu-
ary 2013 to June 2019 in the Maria Skłodowska-Curie Me-
morial Cancer Center and Institute of Oncology, Cracow 
branch were analyzed. 137 patients from the group with 
the BRAF mutation who had received IT or TT as first-line 
treatment were selected from this group. First-line IT 
treatment in patients with the BRAF mutation in the scope 
of national drug programs was initiated in 2017 as then 
new indications were included. In all analyzed patients 
data were collected concerning age, sex, location of the 
primary tumor, stage of the disease and type of therapy 
used as first, second and subsequent line. Information con-
cerning the stage of the disease, metastasis location, lactate 
dehydrogenase (LDH) levels (LDH) and ECOG (Eastern 
Cooperative Oncology Group) performance status [17] 
were collected at the start of systemic first-line treatment.
Statistical analysis
To determine the p value of defined factors be-
tween the group treated with IT and the larger group 
treated with TT Fisher’s exact test was used. The final 
points encompassed evaluation of progression-free 
survival (PFS), overall survival (OS) and evaluation of 
the overall response rate (ORR) and disease control 
rate (DCR) defined by the criteria of response evalua-
tion RECIST 1.1. PFS or OS were calculated from the 
beginning of IT or TT to disease progression according 
to RECIST, death or the last documented contact. The 
Kaplan-Meier method was used to evaluate PFS and 
OS with a 95% confidence interval (CI) and survival 
curves were analyzed by log-rank analysis. The Cox 
proportional hazard model was used to evaluate, in 
a multidimensional model, the significance of the effect 
of prognostic variables on PFS and OS at the moment 
of initiation IT or TT therapy. Differences are conside-
red significant if p < 0.05. All statistical analyses were 
performed using the STATISTICA 12 program.
Results
General characteristics of the analyzed group
In the group of 137 patients with advanced/meta-
static melanoma with the BRAF mutation 110 (80%) 
patients received first-line TT therapy and 27 (20%) 
IT. TT in 45 (41%) patients was iBRAF (vemurafenib 
or dabrafenib) and in 65 (55%) iBRAF + iMEK (ve-
murafenib + cobimetinib or dabrafenib + trametinib). 
Before 2017, 64 patients received TT treatment. As IT 
anti-PD-1 (nivolumab or pembrolizumab) was used. 
57 (42%) patients received second line treatment, 
among them 39 patients received the IT-TT sequence 
and 4 patients the TT-IT sequence. In the group re-
ceiving the TT-IT sequence, the second line treatment 
was nivolumab or pembrolizumab (19 patients) and 
ipilimumab (20 patients). In the IT-TT group, the sec-
ond line treatment in all patients was iBRAF + iMEK. 
Third line and fourth line treatment were administered 
to 15 (11%) patients and 3 (2%) patients, respectively. 
In the group receiving TT, there were statistically sig-
nificantly more patients with metastases to the CNS, 
elevated LDH levels and a higher grade of the tumor. 
Precise characteristics of the analyzed group are pre-
sented in Table 1. 
Results of treatment in the whole BRAF+ group
Median overall survival (OS) and progression-free 
survival (PFS) in the whole analyzed group were 14.8 and 
7.4 months, respectively. In monofactorial analysis 
unfavorable effects on OS and PFS were observed for 
metastases to the brain (p < 0.0003 and p = 0.0071, 
respectively), increased LDH levels (p < 0.0001 and 
p = 0.0028, respectively) and ECOG performance 
status > 1 (p = 0.0002 and p = 0.0033, respectively). 
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Table 1. Characteristics of patients in respect to first-line therapy used
Factors IT 
n = 27 (20%)
TT 
n = 110 (80%)
p Whole group 
n = 137
Age Median (years) 59 58 0.5997 59
≤ 65 20 (74%) 78 (71%) 0.9294 98 (72%)
> 65 7 (26%) 32 (29%) 39 (28%)
Sex Male 18 (67%) 60 (45%) 0.2497 78 (57%)
Female 9 (33%) 50 (55%) 59 (43%)
Tumor stage M1a 8 (26%) 15 (14%) 0.0096 23 (17%)
M1b 7 (25%) 17 (15%) 24 (18%)
M1c 10 (37%) 60 (55%) 70 (51%)
M1d 2 (7%) 18 (16%) 20 (14%)
Presence of metastases 
to CNS
No 25 (96%) 92 (84%) 0.0071 127 (93%)
Yes 2 (8%) 18 (16%) 20 (7%)
Number of metastatic 
sites
≤ 2 16 (59%) 50 (45%) 0.2840 66 (48%)
> 2 11 (40%) 60 (55%) 71 (52%)
LDH Normal 22(81%) 44 (40%) 0.0002 66 (48%)
Above normal 5 (19%) 62 (56%) 67 (49%)
No data 0 (0%) 4 (4%) 4 (3%)
LDH (×2) ≤ 2 × normal 26 (96%) 82 (78%) 0.0039 106 (81%)
> 2 × normal 1 (4%) 24 (22%) 25 (19%)
ECOG/PS 0 4(15%) 11 (10%) 0,4326 15 (11%)
1 22 (81%) 84 (76%) 106 (77%)
2 1 (4%) 14 (13%) 15 (11%)
3–4 0 (0%) 1 (1%) 1 (1%)
Localization of primary 
tumor
Skin 24 (89%) 91 (83%) 0,1337 115 (84%)
Mucous membrane 1(4%) 0 1(1%)
From unknown primary tumor 
location
2 (7%) 19 (17%) 21 (15%)
T — anti-PD-1 immunotherapy; TT — targeted therapy with BRAF ± MEK inhibitors; LDH — lactate dehydrogenase; CNS — central nervous system; ECOG/PS 
— performance status
The presence of metastases in > 2 sites had a statistically 
significant unfavorable effect only on OS (p = 0.0113). 
Sex, age > 65 years, location of the primary site did not 
have a statistically significant effect on OS and PFS. 
Treatment results depending on the type of first 
line therapy TT vs. IT in BRAF+ patients
Median overall survival (OS) in the group receiv-
ing TT was 13.3 months whereas median OS was not 
attained in the IT group (median observation in the 
TT and IT groups was TT and IT 22 and 18 months, 
respectively). A statistically significant difference in 
OS was observed between groups treated with TT and 
IT (p = 0.0011) (Figure 1A) as well as between groups 
treated with iBRAF + iMEK, only iBRAF and IT 
(p = 0.0084) and iBRAF + iMEK vs. IT (p = 0.0074) 
(Figure 1B and 1C). A statistically significant dif-
ference was also observed in OS between the group 
receiving TT before 2017 (p = 0.0071) and the group 
treated with IT (Figure 1 D). There was no difference 
in OS between groups receiving TT before 2017 and 
from the beginning of 2017 (p = 0.2634) (Figure 1E). 
Median progression-free survival  (PFS) in the groups 
receiving TT and IT were 7.2 and 9.0 months, respec-
tively, and no statistically significant difference between 
them was observed (p = 0.292). Similarly, there was 
no statistically significant difference in PFS between 
the group receiving IT and the group treated with TT 
iBRAF + iMEK (p = 0.1001), as well as between the 
group receiving IT and the group treated only with 
TT before 2017 (p = 0.3498). A precise analysis of the 
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Probability of overall survival (OS) TT vs. IT (Kaplan-Meier curve)
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Figure 1. Kaplan-Meier survival curves. IT — anti-PD-1 immunotherapy; TT — targeted therapy with BRAF ± MEK inhibitors 
(iBRAF ± iMEK)
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Table 2. Results of treatment depending on the first-line therapy used
Type of therapy IT 
n = 27 (20%)
TT 
n = 110 (80%)
Total 
n = 137 (100%)
OS (median in months)
p = 0.0011
Not reached 12.6 (6.7–24.6) 14.0 (7.2–31.2)
6-month OS 94% 76% 80%
1-year OS 81% 52% 57%
2-year OS 56% 26% 29%
PFS (median in months)
p = 0.292
9.0 (3.7–26.6) 7.2 (4.2–12.7) 7,3 (4.1–14.4)
Response to treatment
CR 4% 5% 4%
PR 41% 58% 55%
ORR (CR + PR) 45% 63% 59%
SD 44% 24% 29%
DCR (CR + PR + SD) 89% 77% 88%
PD 11% 13% 12%
IT — anti-PD-1 immunotherapy; TT — targeted therapy with BRAF ± MEK inhibitors; OS — overall; PFS — progression-free survival; CR — complete response; 
PR — partial response; SD — stable disease; PD — progression of disease; ORR — overall response rate; DCR — disease control rate
Table 3. Cox multifactorial analysis
Analyzed factors PFS OS 
p HR Cl p HR Cl
TT vs. IT 0.9768 1.0 0.6–1.7 0.0753 1.92 0.9–3.9
> 65 vs. ≤ 65 0.5618 0.88 0.6–1.4 0.5968 0.88 0.6–1.4
Female vs. male sex 0.7086 0.92 0.6–1.4 0.6881 0.91 0.6–1.4
Lack of metastases to CNS vs. metastases to CNS 0.0129 0.55 0.3–0.9 0.0021 0.46 0.3–0.8
Number of locations ≤ 2 vs. > 2 0.5334 1.15 0.7–1.8 0.7619 0.93 0.6–1.5
LDH normal vs. elevated 0.0150 0.58 0.4–0.9 0.0019 0.47 0.3–0.8
ECOG ≤ 1 vs. > 1 0.0013 0.38 0.2–0.7 < 0.001 0.28 0.2–0.5
T — anti-PD-1 immunotherapy; TT — targeted therapy with BRAF ± MEK inhibitors; LDH — lactate dehydrogenase; CNS — central nervous system; ECOG/PS 
— performance status
treatment results for group TT and IT is presented in 
Table 2. In multifactorial analysis a statistically signifi-
cant unfavorable effect on OS and PFS was found for 
increased LDH levels, the presence of metastases to 
the CNS and ECOG > 1. The other factors were not 
statistically significant (Table 3). 
Discussion 
In the presented analysis a comparison was made 
between first-line IT or TT treatments in patients with 
advanced/metastatic melanoma with the BRAF muta-
tion. This is one of the very few analyses which encom-
pass very homogeneous patient groups. All patients were 
treated in the frame of national drug programs and thus 
had to fulfil the same criteria for inclusion.
Among the first trials which determined the ef-
fectiveness of using immunotherapy before or after 
iBRAF were those performed by Ascierto et al. and 
Ackerman et al. [24, 25]. In these trials. ipilimumab 
was mainly used for immunotherapy and it was shown 
that immunotherapy administered before iBRAF does 
not decrease their effectiveness [24, 25]. Subsequent 
trials and (indirect) analyses confirmed that the use of 
immunotherapy in first-line treatment in patients with 
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a BRAF mutation could be a better option than targeted 
therapy [22, 23, 26].
Our analysis indicated higher effectiveness in first-
-line IT as compared to TT treatment in respect to OS 
(p = 0.0011) and lack of differences in respect to PFS 
(p = 0.292). This was, however, not confirmed in multifacto-
rial analysis, which could be due to the small group receiving 
IT. Moser et al. and Schilling et al. who analyzed larger 
patient groups showed greater effectiveness in respect to OS 
for immunotherapy in first-line treatment in patients with 
advanced/metastatic melanoma with the BRAF mutation 
[20, 23]. In both these analyses, the OS for TT were similar 
(13.2 and 12.4 months) to our results (13.3 months) which 
indicates that the groups were similar and thus can confirm 
the similarity of the remaining results. It is worth mentioning 
that when immunotherapy was used in the BRAF+ group 
of the CheckMate067 trial, better results were obtained for 
combined anti-PD1 and anti-CTLA-4 immunotherapy than 
for anti-PD-1 monotherapy.
As recruitment of patients for IT treatment started 
in 2017, analysis of groups treated before 2017 and from 
2017 was performed. The aim was to check if differences 
in OS between groups treated with TT and IT could 
be due to the fact that from 2017 patients with a worse 
prognosis qualified for TT treatment. No statistically 
significant difference was found for OS for patients 
receiving TT before and after 2017. A statistically signif-
icant difference was observed for patients treated with 
TT before 2017 and IT. The effectiveness of therapy with 
iBRAF, iBRAF + iMEK and IT was also compared. In 
all cases, IT was shown to prolong OS. It is worth noting 
that the results of treatment are worse in the analyzed 
group than in clinical trials, but better than in historical 
groups before new therapies were introduced.
Of course, our analysis has some limitations. First, it 
is retrospective, second, we compare small groups and 
moreover, they are unequal in size. Also, the fact that 
in the group receiving TT there were more patients with 
metastases to the CNS and elevated LDH levels (thus 
unfavorable prognostic factors) can affect the results 
of our analysis. Therefore, in order to unequivocally 
compare the effectiveness of TT and IT prospective, 
randomized trials should be conducted. 
It can be stated with considerable certainty that in 
patients with advanced/metastatic melanoma with the 
BRAF mutation without rapid progression IT should be 
considered as first-line therapy.
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